Canaccord Genuity Downgrades Resmed to Hold From Buy
The firm did not publish a price target with the change, and the stock's last close before the action was $229.94.
Resmed RMD
Resmed Inc · NYSE · Surgical & Medical Instruments & Apparatus
$232.94+1.30%close on Nov. 2, 2026 · volume 1.6M · Yahoo Finance
Price, last 50 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 23, 2026 | Michael J. Rider Global General Counsel | Sold 10b5-1 plan | 400 | $255.00 | $102,000 |
| Oct. 7, 2026 | Michael J. Farrell Chairman and CEO, director | Sold 10b5-1 plan | 4,991 | $226.33 | $1.13 million |
| Sept. 8, 2026 | Michael J. Farrell Chairman and CEO, director | Sold 10b5-1 plan | 4,991 | $222.44 | $1.11 million |
| Sept. 2, 2026 | Peter C. Farrell director | Sold 10b5-1 plan | 970 | $234.73 | $227,688 |
| Aug. 7, 2026 | Michael J. Farrell Chairman and CEO, director | Sold 10b5-1 plan | 4,991 | $205.69 | $1.03 million |
| Aug. 5, 2026 | Peter C. Farrell director | Sold 10b5-1 plan | 8,000 | $225.00 | $1.80 million |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 18 →Results of operations and financial condition · Other events · Financial statements and exhibits
AI summary, unreviewedResMed Q1 fiscal 2027 non-GAAP EPS $2.91 beats $2.67 consensus on $1.415 billion revenue; full-year guidance reiterated